Hypertensive patients over the age of 60 years were admitted to a double-blind placebo-controlled trial. Patients in the actively treated group received a combined potassium-losing and -sparing diuretic (triamterene 50 mg plus hydrochlorothiazide 25 mg; n = 416); this dose could be doubled and methyldopa (up to 2g, daily) was added in 35% of patients when blood pressure remained high. The placebo group (n = 424) received matching capsules and tablets. Adverse effects were assessed in the double-blind period of the trial by calculating the incidence of abnormal biochemical results, investigator reports of diseases and prescriptions of concomitant therapy and a self-administered symptom questionnaire completed by patients. In 1000 hypertensive subjects over 60 years of age, 1 year of active treatment would prevent 11 fatal cardiac events, 6 fatal and 11 non-fatal strokes and 8 cases of severe congestive heart failure. No unexpected adverse treatment effects were observed. A significant excess incidence rate @er 1000 person years) was found in the active group compared with placebo for: (1) impaired renal function, a serum creatinine > 180 pmolll (2.0 mgldl); (2) mild hypokalaemia, a serum potassium < 3.5 rnmolll; (3) reports of gout; and (4) an elevated serum uric acid >0.52 mmolll in men or >0.46 in women. Elevated blood sugar and prescriptions for hypoglycaemic drugs tended to be more frequent in the actively treated group, but this difference was not statistically significant. In both groups, there was a low incidence ( < 7 per 1000 person years) of anaemia and depression and diseases of the liver, gall bladder or pancreas. More patients reported a dr, mouth, blocked nose and diarrhoea in the active treatment group compared with placebo (P < 0.05). Dry mouth and diarrhoea were associated with methyldopa rather than diuretic. We conclude that the adverse effects do not outweigh the benefits of treatment in preventing stroke events, cardiac deaths and heart failure.
Introduction
The European Working Party on High Blood Pressure in the Elderly (EWPHE) carried out a double-blind randomized placebo-controlled trial of antihypertensive treatment in 840 patients over the age of 60. l'he principal results have been published previously [I] and showed a sisnrficant reduction in cardiovascular mortality in the actively treated group compared with placebo. Subsequent analyses showed that these reductions applied to both men and women but decreased with advancing age, with minimal treatment effect shown in patients over the age of 80 years [2] . However, a comprehensive assessment of the benefits of treatment requires that adverse effects are also considered. These may range from an increased morbidity to symptomatic side effects. In this paper, we present the results of analyses of adverse effects.
Methods
The study protocol has previously been published in detail [3] . In summary, patients aged over 60 years, with a sitting blood pressure on placebo within 160-239 mmHg systolic and 90-119mmHg diastolic, were randornized to double-blind treatment. In the active treatment group (n = 416), therapy started with a capsule of a diuretic (50mg triamterene plus 25mg hydrochlorothiazide, daily); after 2 weeks, the dose could be increased to two capsules per day and, if the blood pressure remained high after 1 month, methyldopa tablets (500 mg) were added, starting with half a tablet daily and increasing to four tablets daily. In the placebo group (n = 424), placebo capsules and tablets were matched to active treatment in taste, shape and colour. Information on concomitant diseases and symptoms was recorded at entry to the study and at yearly intervals, and coded according to the 8th Revision of the International Classification of Diseases (ICD) [4] . Details of concomitant non-antihypertensive therapies and routine laboratory values were available at entry and at 3-monthly intervals throughout the trial. Drug therapy was coded both by generic name and class of therapy. AU coding was blind to the randornized treatment. This information on disease, symptoms and therapy was also recorded when the patient left the trial, either at the time of its termination in July, 1984, or for a study-terminating event or defaulted from follow up. Patients were asked to complete a questionnaire at entry and at each yearly visit. AU questions had been published previously and were shown to be sensitive either to changes in blood pressure or to be associated with antihypertensive drug treatment [5-71. Questions on the following symptoms were included: faintness, sleepiness, hours of sleep, weakness in the limbs, a slowed walking pace, headache, blurred vision, depression, diarrhoea, nocturia, dry mouth, nasal stuffiness, nausea, poor mental concentration and vivid dreams. Where appropriate, the questions had a time duration of the preceding 3 months and were translated from English into the various European languages, then translated back by a person who had not seen the original Enghsh version until an acceptable agreement was obtained. Two countries and four centres within other countries did not collect questionnaire data. The countries with patients completing questionnaires were Finland, United Kingdom, Belgium, Italy, The Netherlands, Ireland, Portugal and Federal Republic of Germany.
Method of analysis
The incidence of diseases was established as follows. At entry to the trial, ICD codes were examined and only patients with no record of the particular ICD code were included, i.e. the analysis was restricted to 'new' cases.
AU follow up record forms for each patient, including the study termination form and death certificate when appropriate, were examined for the specific ICD code. The first ICD code entry was taken as the initiation of the disease or symptom. The number of patient years until the first event was recorded for each patient. For patients with no went, the total number of person years in the trial was recorded. Incidence rates were calculated in the usual manner, as the number of events per person years at risk. Prescription rates for non-antihypertensive therapy and incidence rates for abnormal laboratory values were also established in this way, taking only the first record of a particular prescription or an abnormal value. Incidence rates for various diseases, symptoms and prescriptions were compared according to the randomized group, using rate differences and their 95% confidence intervals. The analysis was an 'on randomized treatment' analysis, not an 'intention to treat analysis' as data were not available for the latter. The questionnaire data were analysed according to the prevalence of symptoms at given time intervals according to randomized treatment.
Results lncidence of disease during the trial
Conditions occurring wit!! a rate > 5 per 1000 person years in either treatment group are given in Table 1 . An excess of clinical reports of gout (F < 0.05) was found in the actively treated group. Diabetes was also more common, but the 95% confidence intervals included zero rate difference. Clinical reports of headache were significantly fewer in the actively treated group (P < 0.01). The investigators tended to report depression more frequently in the actively treated group, an increase of 7 per 1kW person years (95% confidence interval, -0.5 to + 13.9).
Both the active and placebo treatment groups had sirnilar rates for malignant neoplasms ( < 20 per 1000 person years), fractures (12 per 1000 person years) and diseases of the stomach and gall bladder ( < 7 per 1000 person years). Anaemia, Parkinsonism, disorders of the pancreas and liver disease had an incidence of < 5 per 1000 person years.
lncidence of abnormal laboratory biochemical values
As shown in Table 2 , in the active treatment group, the rates of elevated serum uric acid and serum creatinine and low serum potassium were higher (P < 0.001) than in placebo-treated patients. Abnormal glucose tolerance test results tended to occur more frequently on active treatment.
due to the small number of questionnaires in each treatment group.
Incidence of concomitant drug treatment
Since other workers have shown that women tend to The incidence of concomitant drug treatment was simihave higher reporting rates for symptoms, it was imporlar in the placebo-and active-treatment groups for most tant to check for bias in the questionnaire data, occurring drugs, with the exception of P-blockers for short-term due to a differential response rate by men and women use ( < 3 months), which were prescribed less frequently in the treatment groups. A very similar response rate for in the active group; 5 per 1000 person years on active men and women was found.
treatment compared with 13 per-1000 person years on Table 3 shows the prevalence of m p t o m s in the activeplacebo ( P < 0.05). Again, a m d e n c~ for diabetes to be and placebo-trament groups up to year 3. Ce-n sympmore common on active treatment was reflected in an intoms were simCantly more on active treat crease in h~g l~c a e m i c drugs; 22 per lrn person years merit than placebo: a dty mouth (and the complaint that on active treatment compared with 15 Per Person as interfered with eating), nasal stufiness and years on placebo (95% confidence intervals for the difdiarrhoea ference, -4 to + 17).
Symptoms sgruhcantly associated with active treatment
Questionnaire data were further investigated by comparing patients on active Response rates were calculated for the participating cendiuretic with those on active diuretic plus methyldopa at tres overall, and by treatment type and sex. years 1, 2 and 3. A dry mouth was significantly related to The response rate was 59% at 1 year, 61% at 2 years and treatment with methyldopa plus diuretic (57% at year 1 64% at 3 years. The number of patients declined with and 60% at year 3) compared with diuretic only (27% length of follow up (due to deaths, withdrawals and stopat year 1 and 40% at year 3; P < 0.001 and P < 0.05, ping of the trial), so that by 5 years, questionnaire data respectively). A dry mouth interfering with eating was were available for 113 out of 178 patients. Data for years reported consistently higher by patients on methyldopa 4 and 5 after entry have not, therefore, been presented plus diuretic (23%, 20% and 19% at years 1, 2 and 3, re- spectively) compared with diuretic alone (6%, 11% and 8%; P < 0.05). Diarrhoea was also associated more with nlethyldopa plus diuretic (36%, 30% and 34% at years 1, 2 and 3, respectively) compared with diuretic only (25%, 2196 and 16%; P < 0.05 at year 3).
Discussion
Overall, no unexpected side effects of active treatment were found. Hypokalaenlia, glucose intolerance and increased serum uric acid and creatinine levels have frequently been reported in elderly patients treated with diuretics 18-111 and in interim reports from this trial [12, 13] . The itnportance of the data presented in this paper is the quantification of adverse drug effects which allows the 'Overall Balance Sheet' to be drawn up. The problem remains of comparing important benefits with adverse effects of treatment that range from the relatively trivial to more serious. Table 4 shows that in 1000 hypertensive subjects over 60 years of age, 1 year of treatment wid1 triamterene plus hydrochlorothiazide, and with additional methyldopa in one-third, would prevent 11 fatal cardiac events, 6 fatal and 11 non-fatal strokes and 8 cases of severe congestive heart failure. However, active treat-' tnetlt was also associated wid1 four clinical reports of gout, nine of diabetes (an abnormal glucose tolerance test), 23 of an elevated serum creatinine 2 180 pmoVI, 71 of mild llypokalae~nia (serum potassium < 3.5 mmoVI), 71 self-reports of diarrhoea and 124 of dry mouth. Most would agree that the benefits of treatment outweigh dle disadvantages, but the adverse effects must be considered 'P < 0.05, "P < 0.001, "'P < 0.0001, difference between active and placebo rates. t, A full description of these conditions is given in the text.
Adverse effects were considered to be associated with diuretic treatment, with the exception of dry mouth and diarrhoea which were mainly associated with methyldopa.
Deteriorating renal function o n active treatment was also shown by an average rise of 15 p m o u in serum creatinine conipared with no change in the placebo group. The incidence of abnor~nally high creatitline levels, 2 180 pmol/l (2 mg/dl), occurred in 42 patients o n active treaunent compared with 12 on placebo, an excess rate of 23 per thousand person years, ( P < 0.0001). There was a ten-dency for these levels to be sustained. Of the 42 active patients with a reading during the trial of 2 180 pmoVl (2 mg/dl), 21 had at least one further reading during the trial of tlus value or above, 10 patients had a further reading of 2 130 pmol/l (1.5 mg/dl) and 11 patients had no further readings. Similarly, of the 12 placebo patients with a creatinine level 2 180 pmoVl(2 mg/dl), 8 patients had at least one further reading of this value or over and three patients had readings of 2 130 pmoVl (1.5 mg/dl). However, considering all patients, in only two on active treatment and two on placebo did serum creatinine levels rise as high as 2 265 pmoVl(3 mgldl). A protocol withdrawal criteria was an increase of serum creatinine of 2 100%. Five patients on active treatment and one on placebo were withdrawn for tlus reason. One patient on active treatment and none on placebo died from renal disease. Despite the use of potassium-sparing diuretic, potassium levels fell in the actively treated group. An increased incidence of abnormally low potassium values ( < 3.5 mmol/l) was found in 122 patients on active treatment compared with 50 on placebo, an excess rate of 71 cases per thousand person years. The prognostic s i mcance of hypokalaemia remains uncertain. In a substudy of the Medical Research Council (MRC) trial, ventricular ectopic beats were found to be significantly higher in those receiving long-tenn thiazide treatment than their age-and sex-matched controls [19] . Short-term treatment with bendrofluazide alone did not increase the number of extra systoles, but a lower ectopic rate was observed in the group treated with bendrofluazide plus potassium supplementation for the same period. The overall results of the MRC trial did not show any important increase in cardiac mortality as a result of diuretic treatment. The relative risk for sudden death in men receiving bendrofluazide was 1.4 compared with placebo (95% confidence interval, 0.8-2.3) and, in the first year of treatment, 3.4 (95% confidence interval, 0.9-15.4) [20] , and Miall and Greenberg [20] suggested that any possible coronary hazard from thiazide diuretics was concentrated in the first year. No adverse effect on cardiac events in activelytreated patients was seen in the EWPHE trial; moreover, cardiac mortality was significantly reduced on active treatment. It is possible that this difference in diuretic effect was due to a lower level of potassium depletion in the EWPHE trial (reduction of 0.2 mmol/l) compared with a reduction by bendrofluazide of 0.6rnrnoM in the MRC trial. We have previously described a deterioration in glucose tolerance on active treatment compared with placebo [ l l ] in all patients entering the trial. The present analysis excluded patients with glucose intolerance at entry and showed a small but non-si&cant deterioration with active treatment. Moreover, fasting glucose levels rose on average by 5 mg/dl on active treatment compared with no change on placebo [ 121. The clinical importance of these increases can be judged from the incidence of physician reports of diabetes and the number of new prescriptions for hypoglycaemic drugs. There were 29 physician reports of diabetes on active treatment and 20 on placebo, a rate excess of 6 per 1000 patient years on active treatment (95% confidence interval, -5 to + 17). Similarly, 28 patients on active treatment received a new prescription for hypoglycaemic drugs compared with 18 in the placebo group, a rate excess of 6.7 per 1000 patient years (95% confidence interval, -4 to + 17). These data suggest that the consequence of a rise in glucose on active treatment is an annual excess of 6 patients in 1000 developing diabetes considered worthy of treatment, while including untreated abnormal glucose tolerance tests gives an excess rate of 9 cases. There was no evidence of an excess of diseases of the gall bladder, pancreas or liver with active treatment. Other studies have provided cordicting evidence on the association between thiazide diuretic use and increased risk of cholecystitis [21-231. Pancreatitis has also been reported as an adverse effect of thiazide treatment [24, 25] and liver damage with methyldopa [26, 27] . Clinical reports of iron-deficiency anaemia occurred at a similar rate in both groups. No case of haemolytic anaemia or thrombocytopenia was reported in the present trial.
The incidence of cancer was similar on both active and placebo treatment. The rates were comparable to those described for the community [28] . This does not agree with other data where hypertensives had lower cancer rates than the general population [29] . An excess of two well known side effects of methyldopa was reported: dry mouth and diarrhoea. A comparison with either placebo or diuretic showed no increase of sleepiness, nocturia or weak limbs, occurrences which have been recorded in other studies with methyldopa [301.
In long-term randomized trials, double-blinding, such as in the EWPHE trial, allows a more accurate assessment of adverse events in contrast to single-blind trials where it is difficult to ascribe adverse consequences of treatment impartially due to investigator bias. Moreover, adverse effects reported in most trials are based on prevalence data. In the present trial, the calculation of incidence rates (of abnormal laboratory values, investigator reporting of new dseases and concomitant medication) provides a more valid measure of the magnitude of treatment effects compared with placebo.
